TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2515494

Group type: COMPARATOR
Intervention: Oral zinc acetate (6-month study)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (6-month study)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Oral pergolide mesylate (3-month crossover study)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (3-month crossover study)
Number of subjects: 26
Study: 369642

Group type: EXPERIMENTAL
Intervention: Highly selective vagotomy with excision of the ulcer (HSVE)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Standard Billroth I partial gastrectomy (BI)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Both HSVE and BI
Number of subjects: 56
Study: 31735650

Group type: EXPERIMENTAL
Intervention: We Immunize program (2-hour enhanced training and tailored monthly feedback for 6 months)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (1-hour live immunization update only)
Number of subjects: 62
Study: 30786315

Group type: COMPARATOR
Intervention: Mechanical lithotripsy
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Cholangioscopy-guided laser lithotripsy
Number of subjects: 32
Study: 30075405

Group type: EXPERIMENTAL
Intervention: Educational intervention (at least one session)
Number of subjects: 271

Group type: COMPARATOR
Intervention: Control group (no educational session)
Number of subjects: 271
Study: 26443023

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 20898

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20898
Study: 24217196

Group type: EXPERIMENTAL
Intervention: Yogurt containing Bifidobacterium animalis subsp. lactis DN-173010 probiotic
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control yogurt
Number of subjects: 26
Study: 22231904

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) treatment
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: CDAI-based models and composite outcome (LDA or ACR50)
Number of subjects: 703
Study: 18813910

Group type: EXPERIMENTAL
Intervention: Respiratory physiotherapy (six treatments: positioning, manual hyperinflation, and suctioning in each 24-hour period while on mechanical ventilation)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Standard medical/nursing care (Control Group)
Number of subjects: 144
Study: 17503315

Group type: EXPERIMENTAL
Intervention: Octreotide 30 mg monthly alone
Number of subjects: 71

Group type: COMPARATOR
Intervention: Octreotide 30 mg monthly in combination with rofecoxib (up to 50 mg bid daily)
Number of subjects: 71
Study: 15066461

Group type: EXPERIMENTAL
Intervention: 0.625 mg/day of CEE and calcium
Number of subjects: 300

Group type: COMPARATOR
Intervention: Calcium alone
Number of subjects: 300
Study: 11806623

Group type: EXPERIMENTAL
Intervention: roxithromycin tablets 300 mg once a day (Rx)
Number of subjects: 100

Group type: COMPARATOR
Intervention: amoxicillin/clavulanic acid tablets 875+125 mg twice a day (Acx)
Number of subjects: 100
Study: 9569566

Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg/d)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (healthy women)
Number of subjects: 57
Study: 8059778

Group type: EXPERIMENTAL
Intervention: Perindopril (4 mg/d)
Number of subjects: 490
Study: 3197622

Group type: EXPERIMENTAL
Intervention: Combined endoscopic and surgical intervention
Number of subjects: 728

Group type: COMPARATOR
Intervention: Purely endoscopic procedures
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: Endoscopic papillotomy (EPT)
Number of subjects: 728
Study: 30817982

Group type: EXPERIMENTAL
Intervention: Lifestyle multidomain intervention + omega-3 supplementation (MI + O3)
Number of subjects: 1679

Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation (O3)
Number of subjects: 1679

Group type: EXPERIMENTAL
Intervention: Lifestyle multidomain intervention (MI)
Number of subjects: 1679

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1679
Study: 27902529

Group type: EXPERIMENTAL
Intervention: Exercise (EX) at 70% estimated V˙O2peak for 30 min
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sedentary (SED)
Number of subjects: 20
Study: 25931293

Group type: EXPERIMENTAL
Intervention: Needle aspiration and antibiotics
Number of subjects: 22

Group type: COMPARATOR
Intervention: Antibiotics only
Number of subjects: 22
Study: 23957767

Group type: EXPERIMENTAL
Intervention: 3-day family constellation seminar (active participant and observing participant)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: 3-day family constellation seminar
Number of subjects: 208
Study: 21156772

Group type: EXPERIMENTAL
Intervention: A+‐ICD
Number of subjects: 249

Group type: COMPARATOR
Intervention: DR‐ICD
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Both A+‐ICD and DR‐ICD
Number of subjects: 249
Study: 18667809

Group type: EXPERIMENTAL
Intervention: Virtual reality (VR) training, 3 times a week for 4 weeks
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (no extra computer training)
Number of subjects: 11
Study: 17312647

Group type: COMPARATOR
Intervention: Electrocoagulation (EC)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Injection sclerotherapy (IS)
Number of subjects: 102
Study: 12956654

Group type: EXPERIMENTAL
Intervention: SRP plus minocycline microspheres
Number of subjects: 271

Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 271

Group type: COMPARATOR
Intervention: SRP plus vehicle
Number of subjects: 271
Study: 15919490

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 252
Study: 10604693

Group type: EXPERIMENTAL
Intervention: Antimicrobial-impregnated catheters (minocycline and rifampin)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control catheters
Number of subjects: 124
Study: 8953600

Group type: EXPERIMENTAL
Intervention: Gemcitabine (Gemzar)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Fluorouracil (5‐FU)
Number of subjects: 189
Study: 2030024

Group type: EXPERIMENTAL
Intervention: ceftriaxone
Number of subjects: 123

Group type: COMPARATOR
Intervention: cefoxitin
Number of subjects: 123
Study: 7237920

Group type: EXPERIMENTAL
Intervention: Breath hold at total lung capacity for 15 seconds
Number of subjects: 8

Group type: COMPARATOR
Intervention: Breath hold at total lung capacity for 0 seconds
Number of subjects: 8
Study: 30715534

Group type: EXPERIMENTAL
Intervention: Behavior change techniques (BCTs) used in the exercise intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 30974049

Group type: EXPERIMENTAL
Intervention: Revefenacin 88 μg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Revefenacin 175 μg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pooled data of Revefenacin 88 μg and 175 μg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27690626

Group type: EXPERIMENTAL
Intervention: Extreme prime
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Moderate prime
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (not pregnant)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (pregnant)
Number of subjects: 80
Study: 25523285

Group type: EXPERIMENTAL
Intervention: memantine
Number of subjects: 199

Group type: COMPARATOR
Intervention: antipsychotics
Number of subjects: 199
Study: 24790178

Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg) plus ezetimibe (10 mg) daily
Number of subjects: 6245

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6245
Study: 22534815

Group type: EXPERIMENTAL
Intervention: Bortezomib 1.8 mg/m weekly on day 1 and day 8, carboplatin AUC 6, and bevacizumab 15 mg/kg every 3 weeks.
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Bortezomib 1.8 mg/m weekly on day 1 and day 8, carboplatin AUC 6, and bevacizumab 15 mg/kg every 3 weeks (phase II portion).
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Treatment related grade-3/4 toxicities.
Number of subjects: 16
Study: 19922127

Group type: EXPERIMENTAL
Intervention: Web-based data management system
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Survey of trial personnel
Number of subjects: 105
Study: 17179250

Group type: EXPERIMENTAL
Intervention: Transdermal scopolamine (TDS) 1.5 mg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Droperidol 1.25 mg IV
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg IV
Number of subjects: 150
Study: 15049459

Group type: EXPERIMENTAL
Intervention: DEC 6 mg/kg + ALB 400 mg
Number of subjects: 103

Group type: COMPARATOR
Intervention: DEC 6 mg/kg + ALB placebo
Number of subjects: 103
Study: 11493282

Group type: EXPERIMENTAL
Intervention: Reviparin at a dose of 85 IU anti‐Xa/kg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Reviparin at a bolus of 100 IU anti‐Xa/kg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Nadroparin at a standard dose of 70 IU anti‐Xa/kg
Number of subjects: 15
Study: 9489907

Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole and 150 mg TAP
Number of subjects: 95

Group type: COMPARATOR
Intervention: 20 mg omeprazole
Number of subjects: 95
Study: 7817384

Group type: EXPERIMENTAL
Intervention: Diabetic patients with autonomic neuropathy (Group I)
Number of subjects: 37
Study: 31621257

Group type: EXPERIMENTAL
Intervention: Acupuncture 20 min once a day (Group A)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Acupuncture 30 min once a day (Group B)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Acupuncture 20 min once every 2 days (Group C)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Acupuncture 30 min once every 2 days (Group D)
Number of subjects: 140
Study: 28505961

Group type: EXPERIMENTAL
Intervention: Motor dual-task condition
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Cognitive dual-task condition
Number of subjects: 19

Group type: COMPARATOR
Intervention: Single-task condition
Number of subjects: 19
Study: 25771294

Group type: EXPERIMENTAL
Intervention: Sleep position modification device (active)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Sleep hygiene advice (control)
Number of subjects: 86
Study: 24188203

Group type: EXPERIMENTAL
Intervention: Nebulized high-dose budesonide (BUD group)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 118
Study: 21979395

Group type: COMPARATOR
Intervention: Oral sodium phosphate (NaP)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Oral sodium phosphate (NaP) plus alverine citrate
Number of subjects: 147
Study: 18466681

Group type: EXPERIMENTAL
Intervention: T-614 25 mg daily
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: T-614 50 mg daily
Number of subjects: 280

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: T-614 (both dosages)
Number of subjects: 280
Study: 16527165

Group type: EXPERIMENTAL
Intervention: Regimen 1: zidovudine (AZT), lamivudine (3TC), indinavir (IDV)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Regimen 2: zidovudine (AZT), lamivudine (3TC), ritonavir (RTV)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Regimen 3: didanosine (DDI), estavudine (D4T), indinavir (IDV)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Regimen 4: didanosine (DDI), estavudine (D4T), ritonavir (RTV)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Regimen 1
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Regimen 2
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Regimen 3
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Regimen 4
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: RTV group
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: IDV group
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: RTV patients
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: IDV patients
Number of subjects: 98
Study: 12656541

Group type: EXPERIMENTAL
Intervention: Erythropoietin
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 44
Study: 10942095

Group type: COMPARATOR
Intervention: Tamoxifen (TAM)
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Tamoxifen + Aminoglutethimide + Hydrocortisone (TAM+AG+H)
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Tamoxifen + Fluoxymesterone (TAM+FLU)
Number of subjects: 311
Study: 9014599

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 1488420

Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Pipobroman
Number of subjects: 96
Study: 2938923

Group type: EXPERIMENTAL
Intervention: Floxuridine infusions into the hepatic artery using a totally implantable pump system (Infusaid, model 400)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 22
Study: 31735618

Group type: EXPERIMENTAL
Intervention: Flibanserin 100 mg + ethanol 0.6 g/kg
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Flibanserin 100 mg + ethanol 0.4 g/kg
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Flibanserin 100 mg + ethanol 0.2 g/kg
Number of subjects: 96

Group type: COMPARATOR
Intervention: Flibanserin 100 mg only
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Flibanserin 100 mg with ethanol (0.2-0.6 g/kg)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Flibanserin 100 mg + ethanol (0.4 g/kg and 0.6 g/kg)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Flibanserin 100 mg + ethanol
Number of subjects: 96
Study: 30253968

Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 27427876

Group type: EXPERIMENTAL
Intervention: Efavirenz-based ART
Number of subjects: 219

Group type: COMPARATOR
Intervention: LPV/r-based ART
Number of subjects: 219
Study: 24939642

Group type: EXPERIMENTAL
Intervention: Telenursing consultation (at least once a month) by a qualified, experienced, specialist nurse in pediatric rheumatology
Number of subjects: 56

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 56
Study: 22730760

Group type: EXPERIMENTAL
Intervention: Thin-strut stent (strut thickness of 50 microm)
Number of subjects: 651

Group type: COMPARATOR
Intervention: Thick-strut stent (strut thickness of 140 microm)
Number of subjects: 651

Group type: EXPERIMENTAL
Intervention: Combined 1-year rate of death and myocardial infarction
Number of subjects: 651
Study: 20337610

Group type: EXPERIMENTAL
Intervention: Miltefosine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Hydrocortisone
Number of subjects: 16
Study: 19042327

Group type: EXPERIMENTAL
Intervention: Tobacco use intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 16002827

Group type: EXPERIMENTAL
Intervention: Behavioral treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Structured approaches (meal replacements and food provision)
Number of subjects: 0
Study: 12443521

Group type: EXPERIMENTAL
Intervention: Stop smoking and keep walking regime (intervention group)
Number of subjects: 882

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 882
Study: 10711744

Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 33

Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 33
Study: 7568610

Group type: EXPERIMENTAL
Intervention: Jacobson's muscle relaxation with encouragement of positive self-esteem
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group of 30 students
Number of subjects: 22
Study: 1709335

Group type: EXPERIMENTAL
Intervention: Chomelanum (preparation A)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Lasonil (preparation B)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Ointment base of Chomelanum (preparation C)
Number of subjects: 85
Study: 6791487

Group type: EXPERIMENTAL
Intervention: Verapamil 360 mg daily
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 31014090

Group type: EXPERIMENTAL
Intervention: SAFE-PCI trial patients
Number of subjects: 496

Group type: COMPARATOR
Intervention: Registry patients
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: All groups (including SAFE-PCI and registry patients)
Number of subjects: 496
Study: 29171105

Group type: EXPERIMENTAL
Intervention: Family-support programme
Number of subjects: 124

Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 124
Study: 27148551

Group type: EXPERIMENTAL
Intervention: High-scoring Score 6 (S6) spermatozoa
Number of subjects: 10

Group type: COMPARATOR
Intervention: Low-scoring Score 0 (S0) spermatozoa
Number of subjects: 10
Study: 25064573

Group type: EXPERIMENTAL
Intervention: Individually Tailored Exercise
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Targeted Exercise Adherence
Number of subjects: 500

Group type: COMPARATOR
Intervention: Usual Physiotherapy Care
Number of subjects: 500
Study: 22258291

Group type: EXPERIMENTAL
Intervention: Inhaled sevoflurane
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intravenous propofol
Number of subjects: 20
Study: 20708349

Group type: EXPERIMENTAL
Intervention: Heroin-assisted treatment (HAT)
Number of subjects: 1015

Group type: COMPARATOR
Intervention: Methadone maintenance treatment (MMT)
Number of subjects: 1015

Group type: EXPERIMENTAL
Intervention: Ongoing BZD use
Number of subjects: 1015

Group type: EXPERIMENTAL
Intervention: Regular prescription of BZD
Number of subjects: 1015

Group type: EXPERIMENTAL
Intervention: Baseline BZD use
Number of subjects: 1015
Study: 18396254

Group type: EXPERIMENTAL
Intervention: Yoga program (six 1-hour sessions during pregnancy)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group (no yoga program)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Yoga program
Number of subjects: 74
Study: 15669014

Group type: EXPERIMENTAL
Intervention: 10 home visits by a project nurse or a medical doctor during the first 2 years after discharge
Number of subjects: 249

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 249
Study: 12814272

Group type: EXPERIMENTAL
Intervention: Standard Treatment (ST) plus Motivational Interviewing
Number of subjects: 120
Study: 10915531

Group type: EXPERIMENTAL
Intervention: 12-week behavioral skills course and 12-week semistructured exercise course followed by a 3-month problem-solving support intervention
Number of subjects: 64

Group type: COMPARATOR
Intervention: 12-week semistructured course including facility orientation and three meetings with a personal trainer
Number of subjects: 64
Study: 8895642

Group type: EXPERIMENTAL
Intervention: Western Ontario and McMaster Universities osteoarthritis index
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Knee Society clinical rating scale
Number of subjects: 71

Group type: COMPARATOR
Intervention: Short Form‐36
Number of subjects: 71

Group type: COMPARATOR
Intervention: Time trade off (utility method of measurement)
Number of subjects: 71
Study: 1804647

Group type: EXPERIMENTAL
Intervention: Terfenadine 60 mg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Pseudoephedrine 120 mg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Terfenadine-pseudoephedrine combination
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 6391829

Group type: EXPERIMENTAL
Intervention: 200 mg meptazinol 4-times daily
Number of subjects: 32

Group type: COMPARATOR
Intervention: 65 mg dextropropoxyphene plus 650 mg paracetamol 4-times daily
Number of subjects: 32
Study: 31738669

Group type: EXPERIMENTAL
Intervention: Unknown-concentric load (UL) with 100/40% of 1RM eccentric/concentric loading
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Unknown-concentric load (UL) with 100/60% of 1RM eccentric/concentric loading
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Unknown-concentric load (UL) with 100/80% of 1RM eccentric/concentric loading
Number of subjects: 17

Group type: COMPARATOR
Intervention: Known-concentric load (KL) with 100/40% of 1RM eccentric/concentric loading
Number of subjects: 17

Group type: COMPARATOR
Intervention: Known-concentric load (KL) with 100/60% of 1RM eccentric/concentric loading
Number of subjects: 17

Group type: COMPARATOR
Intervention: Known-concentric load (KL) with 100/80% of 1RM eccentric/concentric loading
Number of subjects: 17
Study: 30901744

Group type: EXPERIMENTAL
Intervention: Blunt use frequency
Number of subjects: 377

Group type: COMPARATOR
Intervention: Joint use frequency
Number of subjects: 377
Study: 27974394

Group type: EXPERIMENTAL
Intervention: Real-rTMS (10 Hz) applied to the right dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Sham-rTMS
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Real-rTMS (10 Hz)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Baseline (patients with MS compared with healthy controls)
Number of subjects: 17
Study: 26085822

Group type: EXPERIMENTAL
Intervention: N-3 supplementation (5 ml seal oil, 375 mg EPA, 230 mg DPA, 510 mg DHA)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: N-3 supplementation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (5 ml olive oil)
Number of subjects: 30
Study: 25796858

Group type: EXPERIMENTAL
Intervention: COPD
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: COPD combined with CAC
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: CAC in acute phase
Number of subjects: 92
Study: 22577969

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) enjoyment
Number of subjects: 885

Group type: EXPERIMENTAL
Intervention: Teachers' support for PA
Number of subjects: 885

Group type: EXPERIMENTAL
Intervention: Friends' support for PA
Number of subjects: 885

Group type: EXPERIMENTAL
Intervention: Perceived environmental opportunities for PA
Number of subjects: 885

Group type: EXPERIMENTAL
Intervention: Pubertal stage
Number of subjects: 885

Group type: EXPERIMENTAL
Intervention: Self-efficacy related to barriers to PA
Number of subjects: 885

Group type: EXPERIMENTAL
Intervention: Perceived social support for PA
Number of subjects: 885

Group type: EXPERIMENTAL
Intervention: Perceived social inclusion
Number of subjects: 885

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) behavior
Number of subjects: 885
Study: 19054706

Group type: EXPERIMENTAL
Intervention: General flexibility assessment using Beighton score (BS)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Maximal force exertion on a six‐component load cell with different thumb support techniques (T1, T2, T3)
Number of subjects: 38
Study: 17882582

Group type: EXPERIMENTAL
Intervention: Pre-radiation neck dissection (pre-RT ND)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (conventional organ preservation treatment)
Number of subjects: 14
Study: 14997188

Group type: EXPERIMENTAL
Intervention: Hormonal therapy with radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radiation therapy alone
Number of subjects: 0